#United States #Boston #radiopharmaceuticals #Colin Hayward #Ratios Therapeutics

Ratio Therapeutics Welcomes Colin Hayward as Chief Medical Officer

On March 12, 2026, Ratio Therapeutics Inc., a pioneering pharmaceutical company based in Boston, has officially appointed Colin Hayward as their new Chief Medical Officer. This strategic addition comes as Ratio is focused on accelerating the advancement of its innovative radiopharmaceutical pipeline tailored for cancer treatment and monitoring. Dr. Hayward brings with him over 26 years of significant experience within the healthcare sector, especially in the realms of oncology, haematology, and rare diseases.

Dr. Jack Hoppin, the Chairman and CEO of Ratio, expressed confidence in Hayward's appointment, stating, "Colin joins Ratio at an important time as we advance our radiopharmaceutical pipeline and further progress the ATLAS trial, a Phase 1/2 study involving [Ac-225]-RTX-2358 in patients suffering from relapsed or refractory soft tissue sarcomas." This critical trial aims to facilitate new treatment options for a disease that has traditionally posed challenges to both patients and healthcare providers.

Dr. Hayward's extensive background in clinical development and medical affairs has been emphasized as crucial for the guidance of trial design, implementation, and oversight at Ratio. His role is expected to ensure the generation of robust scientific data while steadfastly focusing on optimal patient care.

In his own words, Dr. Hayward shared his enthusiasm for joining the Ratio team during this pivotal moment in the radiopharmaceutical industry: "I am honored to join Ratio during such a dynamic period for the radiopharmaceutical industry. I look forward to collaborating with the talented team to drive the ATLAS trial and our broader clinical programs forward." His commitment to translating innovative radiopharmaceuticals into effective treatments underscores not only Ratio's ambition but also its promise to patients needing novel therapeutic options.

Before his tenure at Ratio, Dr. Hayward held the position of Chief Medical Officer at Telix Pharmaceuticals, where he was instrumental in leading Medical Affairs and Clinical Development teams focusing on oncology, hematology, and rare diseases. His previous responsibilities included overseeing pivotal first-in-human studies and interactions with regulatory bodies like the FDA and various global agencies. His previous roles in companies such as Premier Research, Myriad Genetics, and Roche granted him ample experience in managing international medical affairs and strategic drug development initiatives across a wide array of therapeutic areas.

With a medical degree from the University of London, Guy's and St Thomas's Hospitals, Dr. Hayward is also recognized as a Fellow of the Faculty of Pharmaceutical Medicine, which further reinforces his substantial expertise in the sector.

About Ratio Therapeutics

Ratio Therapeutics Inc. aims to revolutionize the field of oncology by accelerating the research and development of next-generation precision radiopharmaceuticals targeted for solid tumors. The company, headquartered in Boston, boasts a team of diverse experts with a wealth of experience in radiopharmaceutical discovery and development. Ratio's proprietary platforms, Trillium™ and Macropa™, enable them to create specialized heterobifunctional radiopharmaceuticals for therapeutic use and imaging enhancement, thereby improving drug availability and tumor targeting.

In addition to its innovative research, Ratio demonstrates a strong commitment to quality manufacturing through collaboration with PharmaLogic and the establishment of its state-of-the-art facility in Salt Lake City, Utah. This facility ensures a stable supply of high-quality radiopharmaceutical products, underpinning their dedication to advancing patient care.

For more information about Ratio Therapeutics and its innovative work, please visit www.ratiotx.com and follow the company on Twitter (X) and LinkedIn.